Drug Profile

KUP 101

Alternative Names: KUP-101; KUP-101A

Latest Information Update: 27 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kupando
Class Antineoplastics; Small molecules; Vaccines
Mechanism of Action Toll-like receptor 4 agonists; Toll-like receptor 7 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Breast cancer; Infections; Lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

12 Nov 2025 Kupando GmbH plans a phase I trial for Solid tumours (Late-stage disease) in Germany (IV) in January 2026 (CTIS2025-522402-21-00)
12 Sep 2025 Preclinical trials in Breast cancer in Germany (IV) (Kupando pipeline, September 2024)
12 Sep 2025 Preclinical trials in Lung cancer in Germany (IV) (Kupando pipeline, September 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com